IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 5:46 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 5:46 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
Why Is Idexx (IDXX) Down 14.6% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OCPNY vs. IDXX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
OCPNY vs. IDXX: Which Stock Is the Better Value Option?
IDEXX (IDXX) Suffers From Macro Headwinds, Cost Constraints
by Zacks Equity Research
The strengthening of the rate of exchange for the U.S. dollar relative to other currencies has a negative impact on IDEXX's (IDXX) revenues.
IDEXX (IDXX) Q2 Earnings Surpass Estimates, 2022 View Down
by Zacks Equity Research
IDEXX's (IDXX) Q2 top-line benefits from strong sales at the CAG and Water businesses.
Idexx Laboratories (IDXX) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 1.30% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Quotient (QTNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Quotient (QTNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OCPNY or IDXX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OCPNY vs. IDXX: Which Stock Is the Better Value Option?
3 MedTech Stocks That are Likely to Beat This Earnings Season
by Urmimala Biswas
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how STE, TMO and IDXX are poised ahead of their earnings releases.
IDEXX (IDXX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) Q2 performance will likely benefit from strong sales from the CAG Diagnostics and Water businesses.
Idexx Laboratories (IDXX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Idexx (IDXX) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Are Options Traders Betting on a Big Move in IDEXX Laboratories (IDXX) Stock?
by Zacks Equity Research
Investors need to pay close attention to IDEXX Laboratories (IDXX) stock based on the movements in the options market lately.
Steris (STE) Up 1.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Idexx (IDXX) Up 0.3% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
IDEXX's (IDXX) Soft LPD Sales, Margin Pressure Concern
by Zacks Equity Research
Distributor purchasing dynamics have an impact on IDEXX's (IDXX) CAG segment product sales.
Should iShares Russell MidCap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
IDEXX (IDXX) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Strong sales at the CAG and Water businesses drove IDEXX's (IDXX) first-quarter 2022 revenues.
Idexx Laboratories (IDXX) Q1 Earnings Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 0.89% and 0.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA
by Urmimala Biswas
MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.
Earnings Preview: Idexx Laboratories (IDXX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEXX (IDXX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in CAG Diagnostics and Water businesses is likely to have contributed to IDEXX's (IDXX) top line in the first quarter.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
IDEXX (IDXX) CAG Sales Gain Traction, FX Headwind Persists
by Zacks Equity Research
IDEXX (IDXX) has been witnessing continued high CAG Diagnostics recurring revenue growth across major regions with solid gains across its key in-clinic platforms.
Accuray's (ARAY) CyberKnife Effective for Relief From TN Pain
by Zacks Equity Research
Latest data indicates that Accuray's (ARAY) CyberKnife System is effective in providing long-lasting pain relief to patients suffering from TN.